Invivyd WALTHAM, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) is pleased to announce the appointment of Ajay Royan to its Board of Directors. Mr. Royan is a venture ...

This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer .

Invivyd has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500. Comparatively, Genocea Biosciences has a beta of 1.74, meaning that its share price is 74% more ...

March 20, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced financial ...

Invivyd reported Q4 2024 revenue of $13.8 million, highlighting significant growth and ongoing development of COVID-19 treatments PEMGARDA and VYD2311. Invivyd, Inc. reported a net product revenue ...

Invivyd has a fifty-two week low of $0.35 and a fifty-two week high of $4.74. Invivyd ( NASDAQ:IVVD – Get Free Report ) last issued its quarterly earnings data on Thursday, March 20th.

March 20, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases, today announced financial results ...